Our vision is to build Clavis Pharma into a profitable, European oncology company developing and commercialising improved cancer drugs based on our proprietary technologies to the benefit of patients.
We intend to leverage our Lipid Vector Technology (LVT) to continue the development of a strong pipeline of pre-clinical and clinical proprietary new and improved anti-cancer drugs. In addition Clavis Pharma will also explore external cancer drug opportunities to build our future pipeline beyond what is possible using LVT.
We aim to commercialize our products through strategic alliances and partnerships with experienced oncology businesses and, where and when commercially appropriate, by establishing our own commercial organisation.
